ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
chrisau
|
44 |
15K |
10 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
15K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Safety Committee Approves Expansion of Ph I/II DFI Trial
|
|
chrisau
|
27 |
6.2K |
6 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
27
|
6.2K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
chrisau
|
34 |
12K |
19 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
34
|
12K
|
19
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
|
|
chrisau
|
32 |
10K |
7 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
32
|
10K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Entitlement Offer - Announcement of Results
|
|
chrisau
|
13 |
5.5K |
3 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
5.5K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Entitlement Offer - Announcement of Results
|
|
chrisau
|
13 |
5.5K |
3 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
5.5K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Entitlement Offer - Announcement of Results
|
|
chrisau
|
13 |
5.5K |
4 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
13
|
5.5K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Becoming a substantial holder
|
|
chrisau
|
18 |
5.7K |
8 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
18
|
5.7K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Becoming a substantial holder
|
|
chrisau
|
18 |
5.7K |
14 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
18
|
5.7K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Need to push the IV dose higher
|
|
chrisau
|
26 |
10K |
7 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
26
|
10K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
chrisau
|
66 |
17K |
11 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
66
|
17K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: A$6.21m Received from R&D Rebate Payments
|
|
chrisau
|
23 |
10K |
20 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
23
|
10K
|
20
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Expansion and Acceleration of Clinical Programs
|
|
chrisau
|
70 |
26K |
18 |
27/09/22 |
27/09/22 |
ASX - By Stock
|
70
|
26K
|
18
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
18 |
29/08/22 |
29/08/22 |
ASX - By Stock
|
2.1K
|
627K
|
18
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Clinical Trial of R327 I.V. - 6000mg Complete
|
|
chrisau
|
18 |
8.5K |
15 |
22/08/22 |
22/08/22 |
ASX - By Stock
|
18
|
8.5K
|
15
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Positive Safety Data - 4000mg Complete
|
|
chrisau
|
46 |
19K |
14 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
46
|
19K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Clinical Trial R327 Advances to 4000mg
|
|
chrisau
|
15 |
8.1K |
18 |
01/06/22 |
01/06/22 |
ASX - By Stock
|
15
|
8.1K
|
18
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial
|
|
chrisau
|
20 |
8.1K |
5 |
04/04/22 |
04/04/22 |
ASX - By Stock
|
20
|
8.1K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial
|
|
chrisau
|
20 |
8.1K |
11 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
20
|
8.1K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Safety Committee Clears PhI R327 Dose Increase
|
|
chrisau
|
16 |
7.2K |
5 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
16
|
7.2K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Another interview - Proactive
|
|
chrisau
|
13 |
3.8K |
9 |
15/02/22 |
15/02/22 |
ASX - By Stock
|
13
|
3.8K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Third Cohort of PI Clinical Trial
|
|
chrisau
|
37 |
9.8K |
6 |
08/02/22 |
08/02/22 |
ASX - By Stock
|
37
|
9.8K
|
6
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
8 |
08/02/22 |
08/02/22 |
ASX - By Stock
|
2.1K
|
627K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Second Cohort of PI Clinical Trial
|
|
chrisau
|
44 |
12K |
12 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
44
|
12K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Second Cohort of PI Clinical Trial
|
|
chrisau
|
44 |
12K |
9 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
44
|
12K
|
9
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
14 |
17/01/22 |
17/01/22 |
ASX - By Stock
|
2.1K
|
627K
|
14
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
9 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
2.1K
|
627K
|
9
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
8 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
2.1K
|
627K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
chrisau
|
120 |
37K |
16 |
07/01/22 |
07/01/22 |
ASX - By Stock
|
120
|
37K
|
16
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Safety Data from Phase 1 Clinical Trial
|
|
chrisau
|
120 |
37K |
17 |
07/01/22 |
07/01/22 |
ASX - By Stock
|
120
|
37K
|
17
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Update on Phase I/II Clinical Trial for Burn Wound Infection
|
|
chrisau
|
103 |
29K |
11 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
103
|
29K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
News: RCE Recce Pharmaceuticals Gets Ethics Approval To Start Phase 1 Intravenous Clinical Trial
|
|
chrisau
|
43 |
12K |
7 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
43
|
12K
|
7
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
6 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
2.1K
|
627K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Anti-Viral Patent Granted in China
|
|
chrisau
|
55 |
15K |
15 |
20/07/21 |
20/07/21 |
ASX - By Stock
|
55
|
15K
|
15
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Multiple Patients Dosed in Topical Phase I/II Clinical Trial
|
|
chrisau
|
109 |
28K |
9 |
12/07/21 |
12/07/21 |
ASX - By Stock
|
109
|
28K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
|
|
chrisau
|
74 |
22K |
10 |
19/05/21 |
19/05/21 |
ASX - By Stock
|
74
|
22K
|
10
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
16 |
14/04/21 |
14/04/21 |
ASX - By Stock
|
2.1K
|
627K
|
16
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
chrisau
|
370 |
106K |
9 |
01/04/21 |
01/04/21 |
ASX - By Stock
|
370
|
106K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
chrisau
|
370 |
106K |
5 |
31/03/21 |
31/03/21 |
ASX - By Stock
|
370
|
106K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
RCE Media
|
|
chrisau
|
370 |
106K |
6 |
31/03/21 |
31/03/21 |
ASX - By Stock
|
370
|
106K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
|
|
chrisau
|
33 |
8.0K |
18 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
33
|
8.0K
|
18
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Further Encouraging COVID Results at Doherty
|
|
chrisau
|
100 |
22K |
10 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
100
|
22K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
RCE Price prediction At Asx close 31st March
|
|
chrisau
|
43 |
11K |
8 |
19/01/21 |
19/01/21 |
ASX - By Stock
|
43
|
11K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
|
|
chrisau
|
38 |
10K |
12 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
38
|
10K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Encouraging Results Against SARS-CoV-2 Virus
|
|
chrisau
|
81 |
21K |
8 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
81
|
21K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
chrisau
|
109 |
28K |
4 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
109
|
28K
|
4
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
chrisau
|
2.1K |
627K |
5 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
2.1K
|
627K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4C and Activity Report
|
|
chrisau
|
118 |
26K |
6 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
118
|
26K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4C and Activity Report
|
|
chrisau
|
118 |
26K |
9 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
118
|
26K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: HREC Approval to Start Phase I/II Burns Wound Study
|
|
chrisau
|
82 |
24K |
2 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
82
|
24K
|
2
|
|